CordenPharma Acquires Pfizer API Manufacturing Facility in Boulder, Colorado

CordenPharma, a contract development and manufacturing organization (CDMO), has entered into definite agreements to acquire the former Hospira Boulder high-containment API site from Pfizer, the company announced in an Oct. 10, 2017 press release. The closing of the transaction is anticipated to occur in November 2017.

Located in proximity to the existing CordenPharma Colorado facility, Hospira Boulder produces APIs and intermediate products with specialized capabilities in small- to medium-scale highly potent and cytotoxic API manufacturing. Previously owned by Pfizer/Hospira, the 54,000-ft² facility with more than 100 employees has API production capabilities ranging from small scale up to 3000 L.

CordenPharma will also enter into a multi-year supply arrangement with Pfizer, with the expectation that the agreement will help defray costs associated with running the site for the next few years while it adds new client work into the facility.

CordenPharma represents the global pharmaceutical manufacturing and service platform of International Chemical Investors Group (ICIG). “The acquisition will augment CordenPharma’s Highly Potent & Oncology platform and integrated supply service offering in association with its drug product manufacturing expertise in the area of solid dosage and sterile injectables in CordenPharma Plankstadt [Germany] and CordenPharma Latina [Italy], respectively,” said Dr. Achim Riemann, managing director of ICIG, in a press release.

CordenPharma Colorado completed the construction of a new API process bay in 2016, equipped to handle highly potent compounds up to OEB Level 4, to accommodate increasing customer demand in this segment.

Hospira Boulder, to be renamed CordenPharma Boulder, will be managed by Brian McCudden, the current CEO of CordenPharma Colorado, who was responsible for Hospira Boulder during one of his previous assignments as an employee of Hospira.

Source: CordenPharma